My NCBI | Sign In
RSS Settings
  • Search: VEGF and prostate cancer

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination
    Are you looking for gene information?

    vegf vascular endothelial growth factor precursor [Oncorhynchus mykiss]

    vegf in Oncorhynchus mykiss | Homo sapiens | Mus musculus | All 18 Gene records

    Results: 1 to 20 of 639

    1.

    Caveolin-1 regulates VEGF-stimulated angiogenic activities in prostate cancer and endothelial cells.

    Tahir SA, Park S, Thompson TC.

    Cancer Biol Ther. 2009 Dec 19;8(23). [Epub ahead of print]PMID: 19923922 [PubMed - as supplied by publisher]Related articles

    2.

    Runx2 association with progression of prostate cancer in patients: mechanisms mediating bone osteolysis and osteoblastic metastatic lesions.

    Akech J, Wixted JJ, Bedard K, van der Deen M, Hussain S, Guise TA, van Wijnen AJ, Stein JL, Languino LR, Altieri DC, Pratap J, Keller E, Stein GS, Lian JB.

    Oncogene. 2009 Nov 16. [Epub ahead of print]PMID: 19915614 [PubMed - as supplied by publisher]Related articles

    3.

    Interaction among variant vascular endothelial growth factor (VEGF) and its receptor in relation to prostate cancer risk.

    Vancleave TT, Moore JH, Benford ML, Brock GN, Kalbfleisch T, Baumgartner RN, Lillard JW Jr, Kittles RA, Kidd LC.

    Prostate. 2009 Nov 11. [Epub ahead of print]PMID: 19908237 [PubMed - as supplied by publisher]Related articles

    4.

    Caveolin-1 promotes autoregulatory, Akt-mediated induction of cancer-promoting growth factors in prostate cancer cells.

    Li L, Ren C, Yang G, Goltsov AA, Tabata K, Thompson TC.

    Mol Cancer Res. 2009 Nov;7(11):1781-91. Epub 2009 Nov 10.PMID: 19903767 [PubMed - in process]Related articles

    5.

    Overexpression of myosin VI in prostate cancer cells enhances PSA and VEGF secretion, but has no effect on endocytosis.

    Puri C, Chibalina MV, Arden SD, Kruppa AJ, Kendrick-Jones J, Buss F.

    Oncogene. 2009 Oct 26. [Epub ahead of print]PMID: 19855435 [PubMed - as supplied by publisher]Related articles

    6.

    Overexpression of vascular endothelial growth factor C increases growth and alters the metastatic pattern of orthotopic PC-3 prostate tumors.

    Tuomela J, Valta M, Seppänen J, Tarkkonen K, Väänänen HK, Härkönen P.

    BMC Cancer. 2009 Oct 12;9:362.PMID: 19821979 [PubMed - in process]Related articlesFree article

    7.

    Differential expression of the semaphorin 3A pathway in prostatic cancer.

    Yacoub M, Coulon A, Celhay O, Irani J, Cussenot O, Fromont G.

    Histopathology. 2009 Oct;55(4):392-8.PMID: 19817889 [PubMed - in process]Related articles

    8.

    Sodium selenite inhibits the expression of VEGF, TGFbeta(1) and IL-6 induced by LPS in human PC3 cells via TLR4-NF-(K)B signaling blockage.

    Pei Z, Li H, Guo Y, Jin Y, Lin D.

    Int Immunopharmacol. 2009 Oct 5. [Epub ahead of print]PMID: 19811770 [PubMed - as supplied by publisher]Related articles

    9.

    C-end rule peptides mediate neuropilin-1-dependent cell, vascular, and tissue penetration.

    Teesalu T, Sugahara KN, Kotamraju VR, Ruoslahti E.

    Proc Natl Acad Sci U S A. 2009 Sep 22;106(38):16157-62. Epub 2009 Sep 2.PMID: 19805273 [PubMed - indexed for MEDLINE]Related articles

    10.

    Multifunctional role of VIP in prostate cancer progression in a xenograft model: Suppression by curcumin and COX-2 inhibitor NS-398.

    Fernández-Martínez AB, Bajo AM, Valdehita A, Isabel Arenas M, Sánchez-Chapado M, Carmena MJ, Prieto JC.

    Peptides. 2009 Dec;30(12):2357-2364. Epub 2009 Sep 20.PMID: 19772879 [PubMed - as supplied by publisher]Related articles

    11.

    Ets-1 and hypoxia inducible factor-1alpha inhibition by angiotensin II type-1 receptor blockade in hormone-refractory prostate cancer.

    Kosaka T, Miyajima A, Shirotake S, Kikuchi E, Hasegawa M, Mikami S, Oya M.

    Prostate. 2009 Sep 16. [Epub ahead of print]PMID: 19760626 [PubMed - as supplied by publisher]Related articles

    12.

    G-rich Oligonucleotides Inhibit HIF-1alpha and HIF-2alpha and Block Tumor Growth.

    Guan Y, Ramasamy Reddy K, Zhu Q, Li Y, Lee K, Weerasinghe P, Prchal J, Semenza GL, Jing N.

    Mol Ther. 2009 Sep 15. [Epub ahead of print]PMID: 19755960 [PubMed - as supplied by publisher]Related articles

    13.

    The role of vascular endothelial growth factor SNPs as predictive and prognostic markers for major solid tumors.

    Jain L, Vargo CA, Danesi R, Sissung TM, Price DK, Venzon D, Venitz J, Figg WD.

    Mol Cancer Ther. 2009 Sep;8(9):2496-508. Epub 2009 Sep 15.PMID: 19755511 [PubMed - in process]Related articles

    14.

    CD133 is indicative for a resistance phenotype but does not represent a prognostic marker for survival of non-small cell lung cancer patients.

    Salnikov AV, Gladkich J, Moldenhauer G, Volm M, Mattern J, Herr I.

    Int J Cancer. 2009 Aug 12. [Epub ahead of print]PMID: 19676044 [PubMed - as supplied by publisher]Related articles

    15.

    Kisspeptin-10, a KISS1-derived decapeptide, inhibits tumor angiogenesis by suppressing Sp1-mediated VEGF expression and FAK/Rho GTPase activation.

    Cho SG, Yi Z, Pang X, Yi T, Wang Y, Luo J, Wu Z, Li D, Liu M.

    Cancer Res. 2009 Sep 1;69(17):7062-70. Epub 2009 Aug 11.PMID: 19671799 [PubMed - indexed for MEDLINE]Related articles

    16.

    Urine markers in monitoring for prostate cancer.

    Jamaspishvili T, Kral M, Khomeriki I, Student V, Kolar Z, Bouchal J.

    Prostate Cancer Prostatic Dis. 2009 Aug 4. [Epub ahead of print]PMID: 19652665 [PubMed - as supplied by publisher]Related articles

    17.

    Depletion of intrinsic expression of Interleukin-8 in prostate cancer cells causes cell cycle arrest, spontaneous apoptosis and increases the efficacy of chemotherapeutic drugs.

    Singh RK, Lokeshwar BL.

    Mol Cancer. 2009 Jul 31;8:57.PMID: 19646263 [PubMed - indexed for MEDLINE]Related articlesFree article

    18.

    Vascular endothelial growth factor-C protects prostate cancer cells from oxidative stress by the activation of mammalian target of rapamycin complex-2 and AKT-1.

    Muders MH, Zhang H, Wang E, Tindall DJ, Datta K.

    Cancer Res. 2009 Aug 1;69(15):6042-8. Epub 2009 Jul 28.PMID: 19638584 [PubMed - indexed for MEDLINE]Related articles

    19.

    Clinical and pharmacodynamic evaluation of metronomic cyclophosphamide, celecoxib, and dexamethasone in advanced hormone-refractory prostate cancer.

    Fontana A, Galli L, Fioravanti A, Orlandi P, Galli C, Landi L, Bursi S, Allegrini G, Fontana E, Di Marsico R, Antonuzzo A, D'Arcangelo M, Danesi R, Del Tacca M, Falcone A, Bocci G.

    Clin Cancer Res. 2009 Aug 1;15(15):4954-62. Epub 2009 Jul 21.PMID: 19622584 [PubMed - in process]Related articles

    20.

    VEGF Inhibitors and Prostate Cancer Therapy.

    Aragon-Ching JB, Dahut WL.

    Curr Mol Pharmacol. 2009 Jun 1;2(2):161-168.PMID: 19617926 [PubMed]Related articlesFree article

    Supplemental Content

    Filter your results:

    Titles with your search terms

    56 free full-text articles in PubMed Central

    Find related data

    Search details

    » See more...

    Recent activity